LKT Laboratories, Inc.

Carfilzomib

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID C0271
CAS No. 868540-17-4
Chemical Name

Synonym PR-171

Formula $C_{40}H_{57}N_5O_7$
Formula Wt. 719.91
Melting Point
Purity ≥98%
Solubility The solubility of carfilzomib in ethanol is approximately 1 mg/ml and approximately 15 mg/ml in DMSO and DMF. Carfilzomib is sparingly soluble
Store Temp -20˚C
Ship Temp Ambient



Bulk quanitites available upon request

Product ID	Size
C0271	1 mg
C0271	5 mg
C0271	25 mg

Description Carfilzomib is an analog of epoxomicin that functions as a proteasome inhibitor. This drug has been approved for use in humans with multiple myeloma. Carfilzomib binds irreversibly to the 20S proteasome, which exhibits chymotrypsin-like activity and is responsible for degradation of cellular proteins; as a result, concentrations of polyubiquitinated proteins build up, inducing cell cycle arrest at the G2/M phase, apoptosis, and decreased tumor growth.

References

Gu JJ, Hernandez-Ilizaliturri FJ, Kaufman GP, et al. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. Br J Haematol. 2013 Jul 4. Epub ahead of print] PMID: 23826755.

Lee HC, Shah JJ, Orlowski RZ. Novel approaches to treatment of double-refractory multiple myeloma. Am Soc Clin Oncol Educ Book. 2013;2013:302-6. doi: E10.1200/EdBook_AM.2013.33.e302. PMID: 23714530.

Nooka A, Gleason C, Casbourne D, et al. Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. Biologics. 2013;7:13-32. PMID: 23386784